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Abstract
Osteoporosis is one of the most common diseases and can be treated by either anti-resorption drugs, anabolic drugs, or
both. To search for anabolic drug targets for osteoporosis therapy, it is crucial to understand the biology of bone forming
cells, osteoblasts, in terms of their proliferation, differentiation, and function. Here we found that protein palmitoylation
participates in signaling pathways that control osterix expression and osteoblast differentiation. Mouse calvarial osteoblasts
express most of the 24 palmitoyl transferases, with some being up-regulated during differentiation. Inhibition of protein
palmitoylation, with a substrate-analog inhibitor, diminished osteoblast differentiation and mineralization, but not
proliferation or survival. The decrease in differentiation capacity is associated with a reduction in osterix, but not Runx2 or
Atf4. Inhibition of palmitoyl transferases had little effect in p53
2/2 osteoblasts that show accelerated differentiation due to
overexpression of osterix, suggesting that osterix, at least partially, mediated the effect of inhibition of palmitoyl
transferases on osteoblast differentiation. BMPs are the major driving force of osteoblast differentiation in the differentiation
assays. We found that inhibition of palmitoyl transferases also compromised BMP2-induced osteoblast differentiation
through down-regulating osterix induction. However, palmitoyl transferases inhibitor did not inhibit Smad1/5/8 activation.
Instead, it compromised the activation of p38 MAPK, which are known positive regulators of osterix expression and
differentiation. These results indicate that protein palmitoylation plays an important role in BMP-induced MAPK activation,
osterix expression, and osteoblast differentiation.
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Introduction
Bone is a dynamic organ and is constantly remodeled. New
bones are formed by osteoblasts to replace the old ones, which are
resorbed by osteoclasts. A fine balance between bone formation
and bone resorption is needed to maintain an optimal bone mass
[1,2]. Indeed, there exist multiple coupling mechanisms between
osteoblasts and osteoclasts [3]. For example, osteoblasts can
synthesize and secrete cytokines such as M-CSF and RANKL to
promote osteoclastogenesis from hematopoietic stem cells of the
bone marrow. On the other hand, bone resorption releases TGFb
and BMPs that are trapped in the bone matrix, facilitating
osteoblast migration, differentiation and function [4]. Disruption
of the balance between bone resorption and formation usually
leads to osteosclerosis or osteoporosis [2]. Osteoporosis affects one
out of every two women and one out of every four men over age
50, and is regarded as a major public health threat. While there
are some anti-resorption drugs in clinical use, such as SERMs and
bisphosphonates, there is a lack of anabolic drugs. To date,
parathyroid hormone (and teriparatide) and strontium ranelate are
the only available anabolic drugs in clinical use [5,6]. Increasing
efforts are being made to search for more efficient anabolic drugs
with lesser adverse effects.
Osteoblasts are derived from bone marrow mesenchymal stem
cells (MSCs) under the influence of growth factors such as BMPs
and Wnts [2,7]. The two transcription factors that are relatively
specific to osteoblast, Runx2 and osterix (Osx), play essential roles
in osteoblast differentiation from MSC [8–10]. Deletion of either
one by gene targeting leads to the loss of mature osteoblasts and
lack of calcified bones [11,12]. On the other hand, ectopic
expression of Runx2 or Osx enhances osteoblast differentiation
and mineralization [12,13]. Moreover, there is evidence to support
the notion that the levels of Osx determine the differentiation
status of osteoblasts [14–16]. Given the importance of Osx in
osteoblast differentiation and function, it is important to study the
regulation of Osx expression. Recent studies show that Osx can be
induced by Notch, BMPs, and TNF and its expression is further
controlled by posttranslational regulation [17–21]. The induction
of Osx is believed to mediate the effect of BMPs on osteoblast
differentiation. BMPs can transactivate Osx through both the
canonical BMP-Smad1/5/8 pathway and the non-canonical
BMP-MAPK pathway [17–19].
Protein function is affected by its expression level, localization,
interaction with other proteins, and its posttranslational modifica-
tions. Recent studies indicate that many proteins can be modified
by palmitoylation on cysteine residues by a family of proteins that
contain a unique zf-DHHC domain. At least 24 members have
been identified in mammalian genome [22]. This modification
regulates protein localization, trafficking, and stability [23–25]. To
understand the importance of protein palmitoylation in osteoblast
biology, we analyzed the expression of the 24 palmitoyl
acyltransferases (PATs) by RT-PCR and found some of them
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importantly, we found that inhibition of protein palmitoylation
with a substrate analog inhibitor impeded osteoblast differentiation
and function, which are mediated by altered expression of Osx
through the p38 MAPK pathway. This study also suggests that
palmitoylation modifies proteins downstream of BMPR and
upstream of p38 MAPK and this modification might regulate
other cellular events that involve this pathway.
Results
Expression of palmitoyl transferases during osteoblast
differentiation
Protein palmitoylation plays an important role in regulating
localization, trafficking, and degradation of a protein, and its
interaction with other proteins. To learn whether protein palmitoyla-
tion is involved in osteoblast function, we first analyzed the expression
of the 24 potential PATs in calvarial osteoblasts at different stages of
differentiation by RT-PCR (Table 1 for primer sequences). It was
found that 20 out of 24 PATs can be detected (Fig. 1A–C). More
interestingly, DHHC1, 2, 6, 7, 15, 23, 25 were up-regulated in
differentiating osteoblasts compared to non-differentiated cells
(Fig. 1B), suggesting that these PATs might play an active role in
this process. On the other hand, DHHC9, 12, 13, 18 were slightly
down-regulated compared to non-differentiated osteoblasts, while
DHHC4, 5, 8, 14, 16, 17, 19, 20, and 24 showed no alteration at the
mRNA levels (Fig. 1A and 1C). DHHC3, 11, 21, 22 were
undetectable, suggesting that their expression in osteoblasts could be
very low. Note that DHHC10 does not exist. A recent study showed
that in most of the human tissues, 17 of these PATs were expressed
[26]. Our previous studies showed that both DHHC19 and DHHC6
were ubiquitously expressed in both mouse and human tissues [27].
Osteoblasts have many PAT substrates
To confirm that protein palmitoylation does occur in osteo-
blasts, we labeled OBs with
3H-palmitic acid for 24 hours. Total
proteins were separated onto SDS-PAGE gels, which were dried
and exposed to X-ray films. Osteoblasts clearly showed several
radio-labeled bands (proteins with covalent palmitoyl modifica-
tion). The most prominent ones were at the MW of ,20, 36, 45,
80, 135 kDa (Fig. 1D). This pattern is different from that of
Figure 1. Expression of PATs and protein palmitoylation in
osteoblasts. A. RT-PCR analysis of the mRNA levels of the 24 known
PATs during osteoblast differentiation. Primary osteoblasts were
cultured in the differentiation medium for different periods of time.
Total RNA was isolated from these cultures and was then used to carry
out RT-PCR. These PATs were classified into unaltered expression (A),
increased expression (B), and decreased expression (C), in comparison
to the day 1 cultures. D. 2BP was able to inhibit protein palmitoylation
in primary osteoblasts. Primary osteoblasts were treated with 100 mMo f
2BP for 2 hrs and then
3H-palmitic acid was included in the culture
medium for 24 hrs. The cells were harvested and the same amounts of
total proteins were loaded for control and 2BP treated samples. The
SDS-PAGE gel was dried and exposed to x-ray films. The palmitoylated
proteins are radio-labeled. Actin was used as a loading control.
doi:10.1371/journal.pone.0004135.g001
Table 1. The primer sequences for the 24 mouse PATs and
other genes studied here and the sizes of the PCR products.
Gene Forward Reverse Size
Zdhhc1 CACCTGCTCTGCTTCCACAT CTCAGCTGATGCCGAGTAGT 503
Zdhhc2 GGTCTGCCTGATACTCAAGC GTTCCATTCCTCCACAGCAC 561
Zdhhc3 TACAAGTGTCCCAAG TGCTG GGTCCTTCAGACCACATACT 527
Zdhhc4 ACCTTCATCGTCTTGCACCT GGAGTGAATGTTCTGGTGGA 761
Zdhhc5 ACCCTCACCAGTCCGTTATG GGTGTAGGTGCAGAGGTGTG 608
Zdhhc6 TTCGGATTGGCTGCGTTTGC AGTCACCATCACAGGGACAC 612
Zdhhc7 GGTGTGGTTCATCCGAGATG TTCTCGCTCTTCAGCCTCTC 662
Zdhhc8 CGACAATGGGCTGAAAGCTG GTGCAGGTAGGGTGAATGGT 666
Zdhhc9 CTACCTCTTCATCCTCTCTC TCTTCAGGAATGCTGGTGTC 485
Zdhhc11 AGTACTGCCACCTGTGTGAG TTCGGCGAAAGAGTAGACAC 606
Zdhhc12 GTGCTAAGCTCCCTGCTGCT GCAGCCTTCTCTCCAGCAAC 665
Zdhhc13 GACTGGCTCTCTGGACTTCA TAAGCCAAAGCAGCCACACT 531
Zdhhc14 AGCCTGTGTGATAACTGCGT CATGGTACGGCTATGTGCTA 848
Zdhhc15 CGTTCTCTACTGCCTGTACA AACCTGCTACGTTTCCGACT 477
Zdhhc16 CTCATCCTCCGAACCTACTC TCCAGTTGTCCAAGCAGCCA 630
Zdhhc17 ATGGTTCTTCTGGTTCTGGA TCCTTACACATCCATGGTTG 657
Zdhhc18 TCTCCCTCTCCTTCTTGACG CTCCTACCATGCTGGCGTCT 431
Zdhhc19 ACCTTCTTCAGTCTCGTCTC CTACAGTGTTTAGGACGACG 658
Zdhhc20 TCTACACCACATCAGCTTCA CTGGTTTGCAACAGAAGCTT 589
Zdhhc21 TGCCTGGTTGCCTTAGTGAG ACAGGATCTTCCAACGAGTG 555
Zdhhc22 GTGACCTTCGTACTGCAGCT ATTTGTCCTGCTGCTTCGAG 729
Zdhhc23 TGCTGGCACTCTGGTATTAC CAGCTGGATGAGGAAGATGT 742
Zdhhc24 TTCCTGTGTCTCCTGCTTCA AGTCACAAGACCCACATCAC 434
Zdhhc25 TCACACCTACGGACTATGCT CATGGTGCTCACTCACTTTG 576
b-actin AGATGTGGACAGCAAGCAG GCGCAAGTTAGGTTTTGTCA 123
Atf4 TTCCACTCCAGAGCATTCCT CAGGTGGGTCATAAGGTTTG 280
Col1a1 GCAATCGGGATCAGTACGAA CTTTCACGCCTTTGAAGCCA 484
M-CSF CTGACACAGGCCATGTGGAG GAGAGGGTAGTGGTGGATGT 315
Ocn AAGCAGGAGGGCAATAAGGT AGCTGCTGTGACATCCATAC 291
Opg CACCCTGTGTGAAGAGGCCT GCAGGCTCTCCATCAAGGCA 310
Opn TCACCATTCGGATGAGTCTG ACTTGTGGCTCTGATGTTCC 436
Osx TGAGGAAGAAGCCCATTCAC ACTTCTTCTCCCGGGTGTG 197
RankL TACTTTCGAGCGCAGATGGAT GTACGCTTCCCGATGTTTCAT 483
Runx2 CCGCACGACAACCGCACCAT CGCTCCGGCCCACAAATCTC 288
doi:10.1371/journal.pone.0004135.t001
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specific sets of palmitoylated proteins [28]. Taken together, these
results indicate that osteoblasts express many PATs and some
proteins are palmitoylated.
Inhibition of PATs impeded osteoblast differentiation
and mineralization, but not proliferation or survival
To study whether protein palmitoylation plays a role in osteoblast
function, we intended to inhibit protein palmitoylation with PATs
inhibitors and/or to silence PATs with short hairpin RNA. However,
too many PATs are expressed in osteoblasts and antibodies against
these PATs are mostly unavailable, it was not feasible, at this stage, to
silence individual PATs. Instead, we used 2-bromohexadecanoic acid
(2-bromopalmitate, 2BP) to block PAT activity. 2BP is a substrate
a n a l o gi n h i b i t o rt h a ts h o u l dh a v ea ne f f e c to nm o s ti fn o ta l lP A T s
[29]. We found that 100 mM of 2BP was sufficient to repress protein
palmitoylation in osteoblast by 80% (Fig. 1D). In the following
experiments, we used 2BP at the concentration of 10 to100 mMi n
osteoblasts to inhibit PAT activities and check the consequences in
two aspects: differentiation and mineralization.
We first looked at one of the early markers of osteoblast
differentiation, alkaline phosphatase (ALP). It was found that 2BP
had a dosage dependent inhibitory effect on ALP expression.
Fig. 2A shows the ALP staining of osteoblasts cultured in the
differentiation medium, while Fig. 2B shows the quantitative ALP
activities that were normalized to the total protein levels. It is
obvious that inhibition of protein palmitoylation diminished ALP
expression. We then tested the expression of a few other markers
by RT-PCR. It was found that 2BP mainly down-regulated the
mRNA levels of osteocalcin, but not collagen type 1a or
osteopontin (Fig. 2C). More significantly, we found that 2BP
severely inhibited bone nodule formation, a later marker of
osteoblast differentiation and an indicator of osteoblast bone
forming activity (Fig. 2D). These results indicate that protein
palmitoylation is required for osteoblast differentiation into mature
osteocytes. However, treatment of osteoblast with the same
amounts of palmitic acid, the substrate of PATs (.150 mM
palmitic acid showed cytotoxicity in primary osteoblasts), showed
no significant effect on osteoblast differentiation (Fig. 2E). The
reason why higher concentrations of palmitic acid did not enhance
osteoblast differentiation could be that the serum provides
sufficient amount of palmitic acid for protein palmitoylation.
To test whether 2BP has an effect on cell proliferation/survival
in the in vitro differentiation assays, which may indirectly influence
osteoblast differentiation, we first counted the live cells in
osteoblast cultures in the presence or absence of 2BP. No
significant difference was observed (Fig. 3A). Moreover, 2BP
showed no significant effect on the total protein levels of the
osteoblast cultures (Fig. 3B). More importantly, removal of 2BP
from cell cultures led to a recovery of osteoblast differentiation.
Two sets of osteoblast cultures were treated with increasing
concentrations of 2BP for three days. One set was continually
cultured in the presence of 2BP for 4 more days, while the other
set had 2BP washed off and then cultured for 4 more days in the
differentiation medium. It was found that the expression of ALP in
osteoblasts recovered rather well and this was confirmed by the
quantitative ALP assays (Fig. 3C and data not shown). These
results indicate that 2BP, at the concentrations used, has little
effect on cell proliferation and/or survival, at least for a short term.
Instead, it mainly affects osteoblast differentiation.
Down-regulation of Osx by the PAT inhibitor
Osteoblast differentiation is controlled by transcription factors
such as Runx2, Osx, and Atf4. Elevation in any of these
transcription factors promotes osteoblast differentiation while
deletion of any of them leads to defects in osteoblast maturation
and bone calcification [11,12,30]. We used RT-PCR to monitor
the mRNA levels of these transcription factors. Both Osx and
Runx2, but not Atf4, showed an up-regulation during osteoblast
differentiation, with the increase in Osx mRNA levels being much
more pronounced (Fig. 4). 2BP treatment did not significantly
affect the mRNA levels of Runx2 or Atf4, suggesting that Runx2
and Atf4 are unlikely to mediate the inhibitory effect of 2BP on
osteoblast differentiation. In contrast, 2BP treatment diminished
Osx mRNA levels. These results suggest that down-regulation of
Osx might mediate the effect of 2BP on osteoblast differentiation.
It is known that osteoblasts express and secrete cytokines that
promote osteoclastogenesis [3]. We also tested whether inhibition of
protein palmitoylation had any effect on the synthesis of these
cytokines. RT-PCR assays show that both OPG and RankL were
down-regulated during differentiation while the levels of M-CSF
were not altered (Fig. 4). 2BP treatment only slightly decreased the
mRNA levels of RankL (Fig. 4). Since during osteoblast differenti-
ation, RankL down-regulation is associated with Osx up-regulation,
we believe that the further decrease of RankL induced by 2BP is
probably not due to the changes in Osx. These results suggest that
inhibition of protein palmitoylation may not greatly affect the ability
of osteoblast to promote osteoclastogenesis.
p53
2/2 OBs were resistant to PAT inhibitor in
differentiation
To further confirm that Osx mediates the effect of 2BP on
osteoblast differentiation, we used p53
2/2 osteoblasts that have
been shown to have an increased expression of Osx and enhanced
differentiation [16,31,32]. Moreover, elevated expression of Osx,
which was directly repressed by p53, was demonstrated to mediate
the effect of p53 on differentiation. We found that the elevated
levels of Osx was not further induced during osteoblast
differentiation in p53
2/2 osteoblast, and that 2BP showed little
effect on the mRNA levels of Osx either (Fig. 5A). Consistent with
this result, ALP staining was not markedly inhibited by 2BP
(Fig. 5B). Moreover, 2BP showed only a slight effect on bone
nodule formation in p53
2/2 osteoblast cultures (compared to the
Fig. 2D) (Fig. 5C). These results indicate that p53
2/2 osteoblasts
are refractory to the negative effect of 2BP, suggesting that Osx
mediated the effect of 2BP on osteoblast differentiation.
PAT inhibitor compromised BMP2-induced osteoblast
differentiation
In the in vitro differentiation assays, BMPs from the serum or
secreted by osteoblasts themselves are the driving force of
differentiation. It has been shown that the addition of noggin and
chordin to differentiation cultures diminished osteoblast differenti-
ation, which is accompanied by down-regulation of Osx [19]. We
then tested whether 2BP has an effect on BMP2 induced
differentiation. It was found that 50 ng/ml of BMP2 was able to
dramatically up-regulate ALP expression, which was almost
abolished by 2BP (Fig. 6A). More interestingly, BMP2 was able to
markedly up-regulate the mRNA levels of Osx, which was impeded
by 2BP as well (Fig. 6B), supporting the notion that 2BP inhibits
osteoblast differentiation by repressing Osx expression. On the other
hand, BMP2 had minimal effect on the mRNA levels of Runx2.
PAT inhibitor negatively regulated the activation of p38
MAPK but not Smad1/5/8
How does inhibition of protein palmitoylation regulate Osx
expression? Several studies indicate that Osx is under the control
Palmitoylation in Osteoblast
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BMP-MAPK pathway. We found that 2BP had little effect on
Smad1/5/8 phosphorylation in the in vitro differentiation assays
(Fig. 7A). No significant change was observed in the activation of
Erk1/2 either. However, PAT inhibitor seemed to inhibit the
activation of p38 MAPK (Fig. 7A). Since BMPs are the driving
force of osteoblast differentiation and they activate MAPKs, these
results suggest that protein palmitoylation is necessary for the
activation of the p38 MAPK pathway, but not the canonical BMP-
Smad pathway. This conclusion was supported by the finding that
2BP also compromised BMP2-induced activation of both Erk1/2
and p38 MAPKs (Fig. 7B). The failure of 2BP to affect Erk1/2
activation in differentiation assays (Fig. 7A) suggest that other
signaling pathways might have made compensation. The corre-
lation between compromised p38 MAPK activation and the down-
regulation of Osx suggests that protein palmitoylation is involved
in BMPs-induced p38 MAPK activation, Osx expression and
osteoblast differentiation.
Figure 2. Inhibition of protein palmitoylation impeded osteoblast differentiation. A. The effect of 2BP on ALP staining. Primary osteoblasts
were treated with increasing amounts of 2BP for 4 days in differentiation medium and then stained for ALP. B. Quantitation of ALP activities that were
normalized to the protein levels of the cells. C. The effect of 2BP on the expression of several osteoblast differentiation markers. The experiments
were carried out like Fig. 2A and total RNA were isolated from these cells. RT-PCR was carried out to determine the mRNA levels of these markers. The
value of control (lane 1) was set at 1.00. D. The effect of 2BP on bone nodule formation. The experiments were carried out like Fig. 2A. After 21 days in
culture, the plates were stained using a Von Kossa method.
doi:10.1371/journal.pone.0004135.g002
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This study shows that most of the 24 PATs are expressed in
primary osteoblasts, with some showing an up-regulation during
differentiation. In addition some proteins are palmitoylated in
osteoblasts and the modification can be inhibited by the substrate
analog inhibitor, 2BP. It was also found that inhibition of PATs
with the inhibitor impeded osteoblast differentiation and function,
evidenced by a decrease in the expression of ALP, osteocalcin,
Osx, and in bone nodule formation. Moreover, this inhibitor also
compromised BMP2-induced osteoblast differentiation. However,
treatment of the cells with the same concentration of palmitic acid
did not show such effects. In addition, inhibition of PATs showed
little effect on osteoblast proliferation and survival under
differentiation assay conditions. These results suggest that protein
palmitoylation plays an important role in osteoblast differentiation.
How does protein palmitoylation regulate osteoblast differenti-
ation? Our results suggest that Osx might mediate this effect.
Firstly, treatment with PAT inhibitor down-regulated Osx
expression, not Runx2 or Atf4. Secondly, BMP2-induced
osteoblast differentiation was also hindered by the PAT inhibitor
and this was accompanied by a decrease in the expression of Osx,
but not Runx2. Thirdly, when Osx could not be repressed in
p53
2/2 osteoblasts, which showed enhanced differentiation due to
elevated Osx expression [16], osteoblast differentiation was
refractory to the inhibitory effect of the PAT inhibitor. Thus it
appears that protein palmitoylation is required for the basal
Figure 3. PAT inhibitor show minimal effect on proliferation/survival of osteoblast cultures. A. Primary osteoblast cells were cultured in
differentiation medium with different amounts of 2BP for 4 days and the cell numbers in each culture plates were determined by trypan blue
exclusion methods. B. The experiments were done like Fig. 3A and the cells were collected and lysed in the same volume of lysis buffer and the
protein concentrations were determined by the BioRad method. C. Recovery of 2BP treated cells in ALP expression. Primary osteoblasts were treated
with different concentrations of 2BP for three days, washed off, and further cultured in differentiation medium for 4 more days before being stained
for ALP (bottom panel), in comparison to the cells that were treated with 2BP all the time (upper panel).
doi:10.1371/journal.pone.0004135.g003
Figure 4. Regulation of Osx by 2BP. Primary osteoblasts were
cultured in differentiation medium with or without 100 mM of 2BP for
different periods of time. These cells were then collected to isolate total
RNA. RT-PCR was carried out to determine the mRNA levels of these
proteins. The value of control (lane 1) was set at 1.00.
doi:10.1371/journal.pone.0004135.g004
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results also support the notion that Osx might be a critical
transcription factor that integrates many cues to control osteoblast
differentiation. For example, c-Abl, p53, Atm, and p38 MAPK are
all involved in osteoblast differentiation and they all regulate the
expression of Osx, but not Runx2 [16,19,33,34]. One explanation
for the difference between Runx2 and Osx could be that Runx2
induction by BMPs is usually transient and modest, whereas Osx
induction can be long lasting and robust (Fig. 4 and 6).
BMPs are synthesized and secreted by osteoblasts and are the
main driving force of in vitro differentiation [19]. The observation
that PAT inhibitor compromised Osx induction by BMP2 suggests
that protein palmitoylation might be involved in signaling
pathways activated by BMPs. However, PAT inhibitor did not
show a marked effect on the canonical BMP-Smad signaling.
Instead, it compromised MAPK activation at the basal level and in
the presence of BMP2. One possibility is that components of the
non-canonical pathway such as Tak1, Tab1/2, Xiap, MAPKKs,
are palmitoylated [35]. Another possibility is that BMPRs are
palmitoylated and their palmitoylation differentially regulates the
Smad pathway and the MAPK pathway. Indeed, we found that
BMPRI and II could be palmitoylated. We are currently mapping
the palmitoylation sites and studying their role in regulating BMPs
triggered Smad and MAPK pathways (Leong et al, unpublished
results). Further studies are needed to determine how protein
palmitoylation affects MAPK activation through BMP receptors.
This is because BMP-Smad signaling and MAPK activation can
be complex: i) MAPKs are regulated by many cues including
growth factors that are present in the culture medium, and some
types of stress; ii) BMPs have been reported to either activate or
inhibit MAPKs, depending on the cell type and context
[19,36,37]; iii) BMPs are known to require cooperation with other
signaling pathways to control the expression of target genes due to
the nature of Smad binding elements (only 4 bp) [38]; iv) a
crosstalk exists between BMP-Smad signaling and MAPK [38,39].
Thus it is important that caution be exercised in interpreting these
results. Nevertheless, this study provides a new dimension in p38
MAPK activation and osteoblast differentiation. Future study will
focus on identifying the palmitoylation target and studying the
function of the palmitoylation in regulating Osx expression and
osteoblast differentiation.
In summary, this is the first study to show that protein
palmitoylation plays an important role in osteoblast differentiation
and function. It seems that the potential palmitoylation substrates
might regulate the MAPK pathway, especially p38 MAPK, to
regulate Osx expression and osteoblast differentiation. Given the
importance of BMPs activated signaling pathways in bone
remodeling and cancer development, it is worth the effort to further
study how protein palmitoylation affects these signaling events.
Materials and Methods
Isolation, culture and treatment of calvarial osteoblasts
To prepare primary osteoblasts, calvaria were excised from 4–5
newborn pups (p53
2/2 and wild type on a 129/Sv background),
washed in PBS and digested in MEM alpha medium containing
Figure 5. Overexpression of Osx in p53
2/2 osteoblasts rendered resistance to the inhibitory effect of 2BP on differentiation. A. 2BP
treatment did not significantly down-regulate the mRNA levels of Osx. Primary osteoblasts were cultured in the presence or absence of 2BP for
different periods of time and total RNA was isolated and RT-PCR was carried out to determine the mRNA levels of Osx. The value of control (lane 1)
was set at 1.00. B. PAT inhibitor did not markedly affect ALP staining in p53
2/2 osteoblasts. p53
2/2 osteoblasts were treated with different amounts
of 2BP for 7 days and then stained for ALP. C. PAT inhibitor did not markedly affect bone nodule formation in p53
2/2 osteoblasts. p53
2/2 osteoblasts
were treated with different amounts of 2BP for 21 days and then stained for mineralization.
doi:10.1371/journal.pone.0004135.g005
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37
oC five times. The supernatant from the first digestion was
discardedandsupernatantsfromthelastfourdigestionswerepooled.
The cells were washed and plated onto 6 well plates and grown in
MEM alpha medium supplemented with 15% FCS (Research Sera)
and glutamine until confluent. The osteoblast cultures were
amplified to passage 3 before use in further experiments. The mice
were kept at the Biological Resources Center (BRC) of Singapore
and were used for the experiments following protocols approved by
the Institute of Molecular and Cell Biology and BRC. A palmitate
analog inhibitor, 2-bromohexadecanoic acid (Merck, Darmstadt,
Germany) was dissolved in 100% ethanol at a stock concentration of
100 mM and added to cells at the respective concentrations with
ethanol as the control.
Alkaline phosphatase (ALP) staining and quantitation
Calvarial cells were seeded on 12-well plate at a density of
1.5610
5 cells in differentiation medium (growth medium supple-
mented with 50 mg/ml ascorbic acid and 10 mM b-glycerophos-
phate) and incubated at 37uC for 4 or 7 days. For ALP staining,
the differentiation medium was removed and the cells were fixed
with fixative solution [60% v/v acetone and 0.8% v/v citrate
concentrate (Sigma-Aldrich, St. Louis, MO)] for 30 seconds before
rinsing with deionized water for 45 seconds. For the biochemical
assay, cell layer was rinsed twice with Tris buffered saline [20 mM
Tris in 0.9% NaCl, pH 7.4] before harvesting in 500 mlo f5 0m M
Tris, pH 7.4 buffer. The cell suspension was sonicated for 20
seconds. The ALP activity was assayed in 221 assay buffer [0.1 M
221 buffer (Sigma-Aldrich), 10 mM MgCl2, pH 10.3] with
10 mM p-nitrophenylphosphate (Sigma-Aldrich) as the substrate.
The reaction was stopped upon the addition of 0.3 N NaOH and
the absorbance was read at 405 nm. The enzyme activity was then
normalized with the protein concentration.
Bone nodule formation
Calvarial cells were seeded as for ALP staining but were
incubated for 14 and 21 days. Cells were rinsed twice with Tris
buffered saline and followed by fixing with 4% formalin for 5 to
10 minutes. The fixed cells were then rinsed twice with ddH2O.
Mineral deposition was stained with 5% silver nitrate and exposed
under UV until desired intensity was achieved before washing with
ddH2O.
RNA isolation and Quantitative RT-PCR
Total RNA was extracted from cells after rinsing twice with ice-
cold PBS and purified with TRIzolH reagent (Invitrogen)
according to manufacturer’s protocol. cDNAs were synthesized
from 1 mg of total RNA using Reverse-It
TM RTase Blend
(Abgene, Epsom, UK) with Oligo(dT)15. The detection and
Figure 6. PAT inhibitor decreased BMP2-induced osteoblast
differentiation, which was likely mediated by Osx. A. 2BP
diminished the ALP expression induced by BMP2. Primary osteoblasts
were cultured in the presence or absence of 2BP for 1 day, and then
were further cultured in the presence of 50 ng/ml of BMP2 for 4 days.
The plates were then stained for ALP. B. 2BP down-regulated BMP2-
induced Osx expression. Primary osteoblasts were cultured in the
absence or presence of different concentrations of 2BP for a day, and
then further cultured in the presence of 50 ng/ml of BMP2 for 16 hrs.
The cells were collected and total RNA was isolated, which was used to
perform RT-PCR to determine the mRNA levels of Osx and Runx2. The
value of control (lane 1) was set at 1.00.
doi:10.1371/journal.pone.0004135.g006
Figure 7. Inhibition of protein palmitoylation compromised
p38 MAPK. A. 2BP showed an inhibitory effect on p38 MAPK activation
in differentiation assays, without a significant effect on Erk1/2 activation
or Smad1/5/8 activation. Primary osteoblasts were cultured in
differentiation medium with or without 2BP for different periods of
time. Cells were collected for Western blot analysis of the activation of
p38, Erk1/2, and Smad1/5/8. B. 2BP also compromised p38 MAPK
activation in response to BMP2. Primary osteoblasts were pretreated
with PAT inhibitor overnight, and then stimulated with 100 ng/ml of
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tative RT-PCR. The primer sequences for the respective genes are
shown in Table 1. The amplification for each mRNA was
performed in the linear range for RT-PCR by optimizing the
template concentration and limiting the amplification cycles to
below 30 to ensure exponential amplification.
Western blot analysis
The cells were rinsed twice with ice-cold PBS and harvested by
scraping in 80 ml RIPA buffer [50 mM Tris, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.5% (w/v) NaDOC, 0.1%
SDS, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin,
2 mM PMSF, 2 mM NaF, 4 mM Na3VO4], followed by rocking
at 4uC for 30 minutes. The cell lysates were then clarified by
centrifugation at 12,000 g for 10 minutes. The proteins were
quantified using DC protein assay (Bio-Rad, Hercules, CA). 60 mg
proteins were resolved by SDS-PAGE and then electrophoretically
transferred to PVDF membrane. The membrane was blocked with
5% non-fat milk for an hour and probed with the respective
primary antibodies overnight at 4uC. After incubation, the
membrane was washed thrice with TBST for 10 minutes each
and probed with respective secondary antibodies for an hour.
Finally, the membrane was washed thrice with TBST and target
proteins were detected using ECL kit (GE Healthcare, Buck-
inghamshire, UK). The primary antibodies used for analysis were
anti-Erk1/2, phospho-Erk1/2, p38 MAPK, phospho-p38 MAPK,
p53, phospho-Smad1/5/8 (Cell Signaling, Danvers, MA), anti-
Smad1 (Millipore, Billerica, MA), anti-b-actin (Sigma-Aldrich).
Protein labeling with
3[H]-palmitic acid
Calvarial cells were pretreated with 100 mM 2-BP for 4 hours
before the treatment with 50 mCi [9, 10-
3H(N)]-palmitic acid
(Perkin Elmer, Waltham, MA) for 24 hours. Total proteins were
harvested, quantitated and resolved by SDS-PAGE. The gel was
then fixed with acetic acid and methanol for an hour. This was
followed by impregnating the gel with EN
3HANCE
TM (Perkin
Elmer) for an hour and subsequently, precipitating the scintillators
with cold water containing 10% polyethylene glycol 6000 for an
hour. The treated gel was sandwiched between two layers of
cellophane sheets and air-dried before exposing to X-ray film for 3
weeks.
Quantitation and statistical analysis
RT-PCR (negative images of gels) was scanned with a
Molecular Dynamics scanning densitometer. The relative levels
of mRNA of interest were then determined by measuring the
intensity of the corresponding bands. All values were averages of
three experiments and were normalized to the constitutive
expression of the housekeeping genes b-actin. Statistical analysis
was performed using an unpaired t test (STATISTICA software;
StatSoft, Inc.). Significant association was defined when * P,0.05
compared with control.
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